Ardelyx IncNASDAQ:ARDX
- LAST PRICE5.2300
- TODAY'S CHANGE (%)-0.0200 (-0.3810%)
- Bid / Lots5.2200/ 70
- Ask / Lots5.2400/ 21
- Open / Previous Close5.2300 / 5.2500
- Day Range
- 52 Week Range
- Volume25,147
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 20, 2024
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference, from 8:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 11, 2024
DJ Ardelyx Cut to Neutral From Buy by HC Wainwright & Co., from 7:28AM ET on Monday Nov 11, 2024 by Dow Jones
7:28AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 8, 2024
Ardelyx Responds to District Court Decision Granting Motion to Dismiss, from 12:31PM ET on Friday Nov 08, 2024 by Dow Jones
12:31PM ET on Friday Nov 08, 2024 by Dow Jones
Nov 5, 2024
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference, from 8:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
DJ Ardelyx Is Maintained at Buy by Citigroup, from 12:07PM ET on Monday Nov 04, 2024 by Dow Jones
12:07PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ardelyx Inc | 1.3B | -16.8x | --- |
Arcus Biosciences Inc | 1.3B | -4.6x | --- |
Gyre Therapeutics Inc | 1.1B | -51.1x | --- |
Aurinia Pharmaceuticals Inc | 1.3B | -55.0x | --- |
Travere Therapeutics Inc | 1.6B | -4.1x | --- |
Arcutis Biotherapeutics Inc | 1.2B | -6.0x | --- |
Company Information
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Contact Information
- Headquarters
- 34175 Ardenwood Blvd.FREMONT, CA, United States 94555
- Phone
- 510-745-7047
- Fax
- 510-745-0493
Executives
- Independent Chairman of the Board
- David Mott
- President, Chief Executive Officer, Director
- Michael Raab
- Chief Financial and Operations Officer
- Justin Renz
- Executive Vice President, Corporate Development and Strategy
- Mike Kelliher
- Principal Accounting Officer
- Joseph Reilly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $251.8M |
Shares Outstanding | 236.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.81 |
EPS | $-0.31 |
Book Value | $0.72 |
P/E Ratio | -16.8x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -25.44% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
